For a woman who has had breast cancer and completed her treatment, there is still a substantial ongoing risk of her developing another breast cancer, or her original breast cancer returning. For these women, that chance can be up to 1 in 25 per year.

The purpose of the ANZ 0501 / LATER study is to find out whether taking the drug letrozole can prevent or delay recurrence of breast cancer; or prevent new breast cancers from developing in postmenopausal women who have previously been treated for breast cancer with a minimum of 4 years hormonal therapy. It is known that letrozole is effective if taken after diagnosis or soon after hormonal therapy.  The LATER study will determine if letrozole is effective in preventing breast cancer after a longer gap in treatment (1 year or more).

Information about LATER in Australia and New Zealand:

• have previously been diagnosed with breast cancer
• had their breast cancer treated with hormonal therapy for at least 4 years 
• completed their hormonal therapy at least 1 year ago
• have completed menopause; and
• are currently free of breast cancer

Women who would like more information about participating in the ANZ 0501 / LATER trial may register their interest online (see below) or phone freecall
1800 039 634 in Australia or freecall 0800 770 119 in New Zealand. The organisation which is coordinating ANZ 0501 / LATER in Australia and New Zealand, the ANZ Breast Cancer Trials Group, will ensure that the enquiries are forwarded to the nearest local ANZ 0501 / LATER hospital or clinic. As each hospital gains approval to start recruiting trial participants, a local research nurse will respond to these enquiries.